Inhibitor of polyglutamine (polyQ) aggregation (IC50s of 25 and 0.05 μM in recombinant HDQ51 and PC12 cells, respectively); reduces polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice; ameliorates neurodegeneration in a Drosophila model of Huntington’s disease in a dose-dependent manner; decreases huntingtin aggregate size, attenuates neuronal atrophy, and improves motor performance in the rotarod test in R6/2 transgenic mouse model of Huntington’s disease at doses of 100 and 200 mg/kg.